- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- COYA 302, Placebo
- Drug
- Lead sponsor
- Coya Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more
Location Directory
Clinical trials in Ann Arbor, Michigan
This page shows live ClinicalTrials.gov search results for Ann Arbor, Michigan, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
3802
Shown on this page
12
Local exact-city summaries
3802
Based on exact city/state matches in the local index.
Local exact-city recruiting
728
Live official results below use the broader ClinicalTrials.gov location search.
Showing 1–12 of 3,802 matching trials in Ann Arbor, MI.
Indexed local directory records.
Top conditions in local exact-city summaries
Top sponsors in local exact-city summaries
Top therapies in local exact-city summaries
Indexed official records
Open in full search- Conditions
- Endometrial Cancer, Malignant Solid Tumour
- Interventions
- Doxorubicin, Paclitaxel, Puxitatug Samrotecan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 66
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 57 more
- Conditions
- Castration-resistant Prostate Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
- Interventions
- DCC-2812
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • Nashville, Tennessee + 2 more
- Conditions
- Invasive Mold Infections
- Interventions
- Fosmanogepix IV infusion, Fosmanogepix oral tablet, Standard of care antifungal therapy
- Drug
- Lead sponsor
- Basilea Pharmaceutica
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 11 more
- Conditions
- ANCA Associated Vasculitis (AAV)
- Interventions
- Active Comparator, Glucocorticoids, Rapcabtagene autoleucel
- Other · Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 8 more
- Conditions
- Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
- Interventions
- Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Pembrolizumab, Questionnaire Administration, Radiation Therapy
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 128
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 88 more
- Conditions
- Crohn's Disease
- Interventions
- SAR441566, SAR441566 matching Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 19
- States / cities
- Sun City, Arizona • Bristol, Connecticut • Clermont, Florida + 16 more
- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- Cyclophosphamide, Methotrexate (MTX), Mycophenolate mofetil (MMF), Ruxolitinib (Rux), Tacrolimus (Tac)
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 30
- States / cities
- Palo Alto, California • San Francisco, California • Miami, Florida + 23 more
- Conditions
- Untreated Follicular Lymphoma
- Interventions
- Surovatamig, R-CHOP, R-CVP, BR
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,018 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 51
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 45 more
- Conditions
- Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Durvalumab, Patient Observation, Questionnaire Administration
- Procedure · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2039
- U.S. locations
- 230
- States / cities
- Jonesboro, Arkansas • Beverly Hills, California • Loma Linda, California + 186 more
- Conditions
- Healthy, Opioid Use Disorder
- Interventions
- Computer Tasks, Magnetic Resonance Imaging (MRI)
- Behavioral · Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Interventions
- Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 45 Years to 74 Years · Female only
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Kansas City, Kansas • Ann Arbor, Michigan • Columbus, Ohio